Our study found that the role of miR-29 in non-obese T2DM patients with NAFLD may improve hepatocellular inflammation, uric acid metabolism, and delay the process of atherosclerosis by inhibiting JNK-1. This evidence concerns the gene MAPK8 and type 2 diabetes mellitus.